BioMark Competitors

Pink Sheets . USA . 
Stock . BioMark Diagnostics
BMKDF Stock  USD 0.15  0.01  6.25%   
BioMark Diagnostics competes with Neuronetics, Intelligent Bio, Biodesix, Precipio, and ProPhase Labs; as well as few others. The company classifies itself under Healthcare sector and is part of Diagnostics & Research industry. Analyzing BioMark Diagnostics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of BioMark Diagnostics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out BioMark Diagnostics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of BioMark Diagnostics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioMark Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.010.155.38
Details
Intrinsic
Valuation
LowRealHigh
0.010.145.37
Details
Naive
Forecast
LowNextHigh
00.155.38
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.140.160.19
Details

BioMark Diagnostics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BioMark Diagnostics and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of BioMark and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BioMark Diagnostics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
STRR
+ 0.92
PRPH
STRR
+ 0.87
BDSX
PRPH
+ 0.86
BDSX
STRR
+ 0.8
PRPO
QGEN
+ 0.73
INBS
PRPH
+ 0.73
PRPO
  
High negative correlations   
RDNT
- 0.94
PRPH
STRR
- 0.84
RDNT
RDNT
- 0.78
BDSX
RDNT
- 0.65
PRPO
BIAFW
- 0.56
STIM
RDNT
- 0.52
BIAFW

Risk-Adjusted Indicators

There is a big difference between BioMark Pink Sheet performing well and BioMark Diagnostics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BioMark Diagnostics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
STIM  5.31  0.62  0.09  0.35  7.78 
(6.41)
 9.86 
(9.45)
 59.07 
INBS  5.05  0.06 (0.01) 0.41  6.04 
(5.64)
 12.00 
(10.59)
 29.81 
BDSX  2.60 (0.35) 0.00  1.95  0.00 
 0.00 
 5.66 
(5.56)
 29.19 
PRPO  1.96 (0.10) 0.00  1.77  0.00 
 0.00 
 3.85 
(3.88)
 11.81 
PRPH  4.43 (1.65) 0.00  1.69  0.00 
 0.00 
 5.73 
(7.56)
 55.04 
BIAFW  11.07  0.22  0.00 (0.14) 13.09 
(16.02)
 28.21 
(27.40)
 96.67 
RDNT  1.96  0.27  0.16  0.31  1.56 
(2.24)
 3.77 
(2.67)
 22.39 
FONR  1.49 (0.18) 0.00 (0.10) 0.00 
 0.00 
 2.15 
(2.81)
 13.29 
STRR  2.45 (0.53) 0.00  4.40  0.00 
 0.00 
 5.29 
(6.09)
 17.14 
QGEN  1.01 (0.05)(0.09) 0.01  1.21 
(1.06)
 2.07 
(1.95)
 4.70 
All Fundamental Data

BioMark Diagnostics Competitive Analysis

The better you understand BioMark Diagnostics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BioMark Diagnostics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BioMark Diagnostics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BMKDF STIM INBS BDSX PRPO PRPH BIAFW RDNT FONR STRR
 6.25 
 0.15 
BioMark
 5.26 
 1.20 
Neuronetics
 0.61 
 1.64 
Intelligent
 0.76 
 1.31 
Biodesix
 1.52 
 6.00 
Precipio
 2.99 
 0.65 
ProPhase
 7.14 
 0.45 
BioAffinity
 2.12 
 80.59 
RadNet
 1.30 
 15.56 
Fonar
 2.93 
 2.65 
Star
Market Volatility
(90 Days Market Risk)
Out of control
Dangerous
Very risky
Very risky
Not too volatile
Very risky
Out of control
Very steady
Not too volatile
Unstable
Market Performance
(90 Days Performance)
Very Weak
OK
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
High
Very High
Very High
Very High
Below Average
Very High
Low
Very Small
About Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Strong Sell
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
0.35
4.02
2.33
0.64
2.19
4.2
0.02
0.79
8.01
1.36
Net Asset
1.47 M
115.83 M
13.78 M
99.1 M
18.1 M
91.93 M
8.22 M
2.69 B
214.25 M
75.5 M
Profit Margin
N/A
-0.45
N/A
-0.67
-0.23
-1.46
-1.19
-0.0025
0.1
-0.15
EBITDA
(1.22 M)
(22.76 M)
(8.81 M)
(37.1 M)
(4.32 M)
(14.83 M)
(7.63 M)
292.79 M
28.25 M
(1.69 M)
Operating Margin
-15.72
-0.52
-3.86
-0.47
-0.27
-3.16
-0.87
0.0771
0.0514
-0.28
Current Valuation
12.8 M
62.16 M
4.15 M
226.93 M
8.8 M
46.17 M
N/A
6.83 B
86.29 M
39.49 M
Price To Book
N/A
3.72
1.2
7.05
0.72
0.45
N/A
6.53
0.59
0.22
Retained Earnings
(3.47 M)
(376.08 M)
(51.96 M)
(419.57 M)
(98.15 M)
(5.03 M)
(44.6 M)
(79.58 M)
(13.62 M)
(108.09 M)
Current Asset
19 K
N/A
N/A
N/A
N/A
9.73 M
N/A
229.37 M
45.56 M
N/A
Beta
0.66
2.22
4.72
1.21
1.42
-0.095
3.12
1.75
1.19
0.097
Number Of Employees
6
203
50
217
51
113
75
10 K
520
171
Shares Outstanding
83.29 M
30.35 M
4.39 M
145.47 M
1.48 M
23.87 M
N/A
74.03 M
6.27 M
3.22 M
Cash Flow From Operations
(1.2 M)
(32.04 M)
(9.57 M)
(22.87 M)
(3.56 M)
(11.35 M)
(6.04 M)
220.86 M
14.09 M
2.7 M
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
96.3 K
62.47 M
871.44 K
60.69 M
1.12 M
21.38 M
1.58 M
1.49 B
41.68 M
3.61 M
Return On Equity
N/A
-1.0
-1.72
-3.32
-0.29
-0.51
-1.52
0.032
0.0917
-0.1
Z Score
69.8
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-1.45
-0.17
-0.53
-0.23
-0.19
-0.23
-0.7
0.0239
0.0498
-0.0735
Book Value Per Share
-0.009
1.18
2.41
0.19
10.16
2.74
0.52
12.1
25.71
14.63
Number Of Shares Shorted
N/A
969.05 K
564.62 K
388.86 K
6.44 K
245.65 K
N/A
3.48 M
8.39 K
27.97 K
Current Liabilities
480 K
N/A
N/A
N/A
N/A
6.25 M
N/A
156.96 M
20.61 M
N/A
Total Asset
1.47 M
115.83 M
13.78 M
99.1 M
18.1 M
91.93 M
8.22 M
2.69 B
214.25 M
75.5 M
Debt To Equity
N/A
0.63
N/A
3.2
0.064
0.19
N/A
3.2
0.26
0.42
Short Ratio
N/A
4.05
1.25
1.13
0.59
7.04
N/A
6.12
0.49
3.25
Target Price
N/A
2.67
12.0
3.1
19.0
18.5
N/A
90.17
N/A
10.0
Shares Owned By Institutions
N/A
53.32
14.38
42.82
8.79
7.63
N/A
87.19
49.78
8.6
Market Capitalization
11.74 M
34.9 M
6.14 M
197.84 M
8.89 M
16.11 M
N/A
5.84 B
95.29 M
8.72 M
Price To Earning
-8.8
N/A
N/A
N/A
-1.14
6.59
N/A
55.56
12.1
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
2.32
N/A
3.25
Price To Sales
105.81
0.48
2.35
3.02
0.51
0.9
N/A
3.3
0.96
0.19
Net Income
(1.45 M)
(30.19 M)
(10.19 M)
(52.15 M)
(5.85 M)
(16.78 M)
(7.94 M)
3.04 M
10.57 M
25.13 M
Earnings Per Share
-0.014
-1.22
-2.3
-0.37
-1.81
-1.53
N/A
-0.07
1.4
-1.96
Shares Owned By Insiders
54.77
11.0
3.01
48.61
12.98
14.33
N/A
10.62
2.42
28.92
Revenue
43.93 K
71.35 M
3.11 M
49.09 M
15.2 M
44.38 M
2.53 M
1.62 B
102.88 M
45.78 M
Working Capital
(461 K)
73.98 M
3.08 M
6.27 M
541 K
26.73 M
1.72 M
141.82 M
122.47 M
26.07 M
Cash And Equivalents
364.96 K
73.7 M
8.28 M
15.18 M
7.47 M
27.5 M
214.4 K
99.17 M
48.73 M
16.21 M
Cash Per Share
N/A
2.71
0.56
0.36
0.33
1.72
0.08
1.73
7.31
1.08
Gross Profit
43.93 K
49.72 M
326.67 K
24.06 M
2.39 M
70.65 M
N/A
288.77 M
45.75 M
25.88 M
Day Typical Price
0.15
1.18
1.63
1.3
5.93
0.68
0.42
80.03
15.49
2.66
Accumulation Distribution
N/A
9059.51
2590.6
29422.8
0.0333
82676.59
0.18
0.0207
0.0129
460.82
Market Facilitation Index
N/A
0.0
0.0
N/A
0.2
N/A
0.08
1.67
0.2
0.0
Daily Balance Of Power
(9,223,372,036,855)
0.5
(0.12)
(0.09)
0.45
(0.18)
0.375
1.0
1.0
(0.57)
Period Momentum Indicator
(0.01)
0.06
(0.01)
(0.01)
0.09
(0.02)
0.03
1.67
0.2
(0.08)
Rate Of Daily Change
0.94
1.05
0.99
0.99
1.02
0.97
1.07
1.02
1.01
0.97
Day Median Price
0.15
1.17
1.62
1.3
5.9
0.7
0.41
79.76
15.46
2.67
Price Action Indicator
(0.01)
0.06
0.015
0.01
0.15
(0.06)
0.055
1.67
0.2
(0.06)
Relative Strength Index
40.69
52.26
50.15
51.74
41.5
19.0
43.13
64.31
60.8
23.45
Coefficient Of Variation
(1,159)
880.52
7353.65
(1,195)
(2,529)
(425.64)
13107.7
718.04
(3,188)
(622.13)
Mean Deviation
2.23
5.31
5.05
2.6
1.96
4.43
11.07
1.96
1.49
2.45
Jensen Alpha
(0.37)
0.6188
0.0575
(0.35)
(0.10)
(1.65)
0.2228
0.2698
(0.18)
(0.53)
Total Risk Alpha
(1.28)
(0.38)
(0.96)
(1.05)
(0.51)
(2.96)
(2.64)
(0.07)
(0.45)
(1.06)
Sortino Ratio
N/A
0.0865
(0.01)
N/A
N/A
N/A
5.0E-4
0.1624
N/A
N/A
Downside Variance
N/A
87.14
40.0
N/A
N/A
N/A
266.68
3.8
N/A
N/A
Standard Deviation
5.19
8.21
6.58
4.31
2.54
7.5
17.44
3.17
2.31
3.3
Kurtosis
9.33
8.38
0.416
12.58
0.2401
18.54
3.34
18.11
7.68
1.37
Potential Upside
N/A
9.86
12.0
5.66
3.85
5.73
28.21
3.77
2.15
5.29
Treynor Ratio
0.5676
0.3479
0.4145
1.95
1.77
1.69
(0.14)
0.3062
(0.1)
4.4
Maximum Drawdown
38.89
59.07
29.81
29.19
11.81
55.04
96.67
22.39
13.29
17.14
Variance
26.95
67.36
43.28
18.59
6.47
56.21
304.15
10.02
5.33
10.89
Market Risk Adjusted Performance
0.5776
0.3579
0.4245
1.96
1.78
1.7
(0.13)
0.3162
(0.09)
4.41
Risk Adjusted Performance
(0.05)
0.0912
0.0187
(0.05)
(0.02)
(0.16)
0.0151
0.1083
(0.02)
(0.11)
Skewness
1.03
(0.76)
0.1568
(2.48)
0.2443
(3.55)
1.17
3.38
1.18
(0.12)
Semi Deviation
N/A
7.78
6.04
N/A
N/A
N/A
13.09
1.56
N/A
N/A
Information Ratio
(0.11)
0.0984
(0.01)
(0.11)
(0.09)
(0.25)
5.0E-4
0.1
(0.09)
(0.20)
Value At Risk
(10.00)
(9.45)
(10.59)
(5.56)
(3.88)
(7.56)
(27.40)
(2.67)
(2.81)
(6.09)
Expected Short fall
N/A
(6.41)
(5.64)
N/A
N/A
N/A
(16.02)
(2.24)
N/A
N/A
Downside Deviation
N/A
9.33
6.32
N/A
N/A
N/A
16.33
1.95
N/A
N/A
Semi Variance
N/A
60.57
36.48
N/A
N/A
N/A
171.3
2.43
N/A
N/A

BioMark Diagnostics Competition Performance Charts

Five steps to successful analysis of BioMark Diagnostics Competition

BioMark Diagnostics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BioMark Diagnostics in relation to its competition. BioMark Diagnostics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of BioMark Diagnostics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BioMark Diagnostics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BioMark Diagnostics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your BioMark Diagnostics position

In addition to having BioMark Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Information Technology ETFs Thematic Idea Now

Information Technology ETFs
Information Technology ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Information Technology ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Information Technology ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in BioMark Pink Sheet

BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY